Khalid Islam - 31 Mar 2022 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Director
Signature
/s/ Khalid Islam by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol
PCSA
Transactions as of
31 Mar 2022
Net transactions value
$0
Form type
4
Filing time
04 Apr 2022, 17:57:30 UTC
Previous filing
19 Apr 2022
Next filing
16 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCSA Common Stock Award +4,392 +6.4% 72,486 31 Mar 2022 Direct F1, F2
holding PCSA Common Stock 120,909 31 Mar 2022 by Elion Oncology, Inc. F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting of time-based restricted shares.
F2 Shares previously reported as indirectly held by Elion Oncology were transferred to the reporting person's direct holdings in a transaction exempt from Section 16 reporting pursuant to Rule 16a-13.